Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma

NCT01245556 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: BMS-908662
DRUG: BMS-908662
DRUG: Ipilimumab
DRUG: Ipilimumab

Sponsor

Bristol-Myers Squibb